PHVS Earnings Date: Nov 11, 2026 (Estimated) — Pharvaris N.V.
NASDAQ · Healthcare · Biotechnology
Updated
When is PHVS's next earnings date?
Pharvaris N.V. (PHVS) is expected to report Q3 2026 earnings on Wednesday, November 11, 2026 at 6:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.82 on revenue of $2.3M.
How did PHVS do in its last earnings report?
In its most recent report on Aug 12, 2026 (Q2 2026), Pharvaris N.V. posted EPS of -$0.81 versus the -$0.75 estimate, a miss of 9.5%. Revenue was $0. The stock's 1-day post-earnings move was +5.9%.
How much does PHVS stock move after earnings?
PHVS beat EPS estimates in 4 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 5.1% (up or down) in the day after earnings.
About Pharvaris N.V.
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-12 | Q2 2026 | -0.75 | -0.81 | -9.46% | $0 | ❌ Miss | +5.93% | +4.88% | +8.98% |
| 2026-05-12 | Q1 2026 | -0.77 | -0.69 | +10.39% | $0 | ✅ Beat | +5.41% | -7.36% | +3.04% |
| 2026-04-02 | Q4 2025 | -0.69 | -0.84 | -21.74% | $0 | ❌ Miss | -3.02% | -8.08% | -0.03% |
| 2025-11-12 | Q3 2025 | -0.78 | -0.70 | +10.26% | $0 | ✅ Beat | +7.01% | -0.62% | -0.58% |
| 2025-08-12 | Q2 2025 | -0.87 | -0.94 | -8.05% | $0 | ❌ Miss | +1.61% | +10.29% | +11.43% |
| 2025-04-07 | Q4 2024 | -0.73 | -0.68 | +6.85% | $0 | ✅ Beat | -7.49% | -15.97% | +17.86% |
| 2024-11-13 | Q3 2024 | -0.67 | -0.85 | -26.87% | $0 | ❌ Miss | +2.54% | +2.30% | -8.18% |
| 2024-08-14 | Q2 2024 | -0.60 | -0.59 | +1.67% | $0 | ✅ Beat | -7.55% | -2.46% | +12.25% |
Showing last 8 quarters.